Edesa Biotech Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.
Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The topical therapy employs a novel mechanism of action, and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in contact dermatitis patients.
We are in the early stages of conducting a 160-patient Phase 2B clinical study evaluating EB01. The company also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications. For example, “EB02” is a sPLA2 inhibitor formulated to treat hemorrhoids, and Edesa is planning to evaluate EB02 in a proof-of-concept study. We are also in discussions with third parties to expand its portfolio with clinical stage therapies to treat other serious skin and gastrointestinal conditions.
Financial Reports and Filings
Investors News Releases
Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada
Fasken Martineau DuMoulin LLP
Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1
Tel: (800) 564-6253